Clinical and biological effects of the umbilical cord-derived mesenchymal stromal cell (UC- MSC) secretome in rheumatoid arthritis: A randomised double-blind placebo-controlled trial
Year: 2026
Type: preprint
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background Although the management of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs) has advanced, a considerable proportion of patients never achieve durable remission, highlighting the need for adjunctive therapies that restore immune homeostasis rather than simply inhibit a individual cytokine. The secretome derived from umbilical cord-derived mesenchymal stromal cell (UC-MSC) is a promising cell-free regenerative candidate, however, randomised trials linking validated clinical outcomes with mechanistic immune biomarkers remain scarce. Methods In this investigator-initiated, single-centre, randomised, double-blind, placebo-controlled trial, 40 patients with moderate RA receiving stable background conventional synthetic DMARD (csDMARD) therapy were randomly assigned (1:1) to receive intramuscular UC-MSC secretome (1.5 mL weekly for six weeks) or matched placebo. The primary endpoint was ACR20 response at week 7. Secondary outcomes included ACR50/70 responses, DAS28, pain intensity, functional disability, safety, and serum TNF-α, IL-6, and TGF-β1 levels to characterise treatment-associated immunomodulation. Results Compared with placebo, the adjunctive UC-MSC secretome produced a significantly greater ACR20 response (75.0% vs 15.0%; risk ratio 5.0, absolute risk reduction 60%, number needed to treat 2) and major clinical response (ACR50/70: 65.0% vs 15.0%). DAS28-CRP, pain intensity, and functional disability also improved significantly. On log-scale reanalysis, TNF-α did not differ significantly between groups after adjustment for age, sex, and baseline level (geometric mean ratio [GMR] 1.07, 95% CI 0.82–1.40), with equivalence testing confirming that the difference lay within a prespecified 1.5-fold margin. IL-6 showed a nominal unadjusted increase (GMR 2.05; P = 0.034) that lost significance after adjustment (GMR 1.51; P = 0.216); TGF-β1 did not differ significantly between groups. These findings indicate the UC-MSC secretome therapy may provide a promising cell-free adjunctive treatment for RA, although its underlying biological mechanism remains to be elucidated. Conclusions Adjunctive intramuscular UC-MSC secretome therapy significantly improved ACR20/50 response, DAS28 score, and pain intensity in patients with moderate RA receiving background csDMARD therapy. Larger multicentre trials with longer follow-up and pathway-specific biomarkers are warranted to confirm long-term efficacy and clarify the underlying biological mechanism. Trial registration ClinicalTrials.gov, NCT07715045
Source: Research Square
Institutions: Sriwijaya University, University of Technology Malaysia
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
Funder: Universitas Sriwijaya
OpenAlex ID: W7236471420
